ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hwang, S. S.
Right arrow Articles by Yim, J-J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hwang, S. S.
Right arrow Articles by Yim, J-J.
Eur Respir J 2009; 33:581-585
Copyright ©ERS Journals Ltd 2009

Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB

S. S. Hwang1, H-R. Kim2, H. J. Kim2, M. J. Kim2, S. M. Lee2, C-G. Yoo2, Y. W. Kim2, S. K. Han2, Y-S. Shim2 and J-J. Yim2

1 Dept of Social and Preventive Medicine, College of Medicine, Inha University, Incheon, and 2 Division of Pulmonary and Critical Care Medicine, Dept of Internal Medicine and Lung Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.

CORRESPONDENCE: J-J. Yim, Division of Pulmonary and Critical Care Medicine Dept of Internal Medicine, Seoul National University College of Medicine, 103 Daehangno, Jongno-gu, Seoul 110–744, Republic of Korea. Fax: 82 220729662. E-mail: yimjj{at}snu.ac.kr

Keywords: Extensive drug resistance, multidrug resistance, streptomycin, tuberculosis

Received: July 1, 2008
Accepted October 20, 2008

Recently, resistance to additional first-line and injectable drugs was reported to be an independent risk factor for adverse outcomes in multidrug-resistant (MDR) tuberculosis (TB) patients. The aim of the present study was to confirm these observations in MDR-TB patients without HIV infection.

MDR-TB patients treated at a tertiary referral hospital in South Korea between January 1996 and December 2005 were included. The unadjusted and adjusted odds ratios of adverse treatment outcome were calculated for resistance to each drug and combination of drugs using simple or multiple logistic regressions.

None of the resistance to additional first-line or injectable drugs was associated with higher odds for adverse treatment outcome in 155 MDR but nonextensively drug-resistant (non-XDR) TB patients. However, streptomycin resistance was associated with 12 times the odds for adverse treatment outcome in 42 extensively drug-resistant (XDR) TB patients. Neither combinations of first-line drugs nor those of injectable drugs were associated with increased odds for adverse treatment outcomes in non-XDR MDR-TB patients or XDR-TB patients.

Only streptomycin resistance among the first-line or injectable drugs was associated with adverse treatment outcomes in extensively drug-resistant tuberculosis patients without HIV infection.




This article has been cited by other articles:


Home page
 Eur Respir JHome page
G. B. Migliori, G. Sotgiu, M. D'Arcy Richardson, R. Centis, A. Facchini, G. Guenther, A. Spanevello, C. Lange, and for TBNET
MDR-TB and XDR-TB: drug resistance and treatment outcomes
Eur. Respir. J., September 1, 2009; 34(3): 778 - 779.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
A. K. Khurana and P. R. Mohapatra
To the Editors:
Eur. Respir. J., September 1, 2009; 34(3): 780 - 780.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
S. S. Hwang and J-J. Yim
From the authors:
Eur. Respir. J., September 1, 2009; 34(3): 780 - 781.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the European Respiratory Society.